Published in Medical Letter on the CDC and FDA, June 5th, 2005
Exjade, also known as investigational agent ICL670, has been granted fast- track status in the U.S. and Switzerland. Priority review has been requested in the U.S. Furthermore, Exjade has received orphan drug status in the U.S., E.U. and Australia.
An easy to administer novel oral iron chelator, Exjade is simply taken once daily, after dispersing tablets in a glass...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.